Kthics Committee (seal),of Beijing Youan Hospital,Capital Medical University
Beijing, Beijing Municipality, 100069, China
NCT Number: NCT05316259
This study is intended to quantify the effect of food on the pharmacokinetics of BPI-16350.
Subjects will be randomized to a crossover sequence at a 1:1 ratio and administered the dose of BPI-16350 on Day 1 in Period 1 and on Day 15 in Period 2 under fasting conditions(Treatment A) or with a high-fat meal(Treatment B).
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
Beijing, Beijing Municipality, 100069, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Administered orally
Time frame: from Day 1 to Day 9 after the first dose and from Day 15 to Day 23 after the second dose
Maximum observed concentration
Time frame: from Day 1 to Day 9 after the first dose and from Day 15 to Day 23 after the second dose
Area under the concentration-time curve from time 0 to time t
Time frame: from Day 1 to Day 9 after the first dose and from Day 15 to Day 23 after the second dose
Area under the concentration-time curve from time 0 to infinity
Time frame: from Day 1 to Day 9 after the first dose and from Day 15 to Day 23 after the second dose
Time to reach maximum observed plasma concentration
Time frame: from Day 1 to Day 9 after the first dose and from Day 15 to Day 23 after the second dose
Half-life time
Time frame: from Day 1 to Day 9 after the first dose and from Day 15 to Day 23 after the second dose
Elimination rate constant
Time frame: from Day 1 to Day 9 after the first dose and from Day 15 to Day 23 after the second dose
Lag Time
Time frame: from Day 1 to Day 9 after the first dose and from Day 15 to Day 23 after the second dose
Percentage of AUCinf due to extrapolation from Tlast to infinity
Time frame: from Day 1 to Day 9 after the first dose and from Day 15 to Day 23 after the second dose
Apparent Oral Clearance
Time frame: from Day 1 to Day 9 after the first dose and from Day 15 to Day 23 after the second dose
Apparent Volume of Distribution
Time frame: from Day 1 to Day 23
Number of subjects with treatment related adverse events
Betta Pharmaceuticals Co., Ltd.
Industry
A Phase 1, Single-center, Open-Label, Randomized, 2 Period Crossover Study to Estimate the Effect of Food on the Pharmacokinetics of BPI-16350 in Chinese Healthy Volunteers After a Single Oral Administration
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details